847227-46-7

Basic information

• Product Name: 4-CYANOMANDELIC ACID ETHYL ESTER
• Synonyms: 4-CYANOMANDELIC ACID ETHYL ESTER;Ethyl 2-(4-cyanophenyl)-2-hydroxyacetate
• CAS NO: 847227-46-7
• Molecular Formula: C₁₁H₁₁NO₃
• Molecular Weight: 205.21
• Mol File: 847227-46-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-CYANOMANDELIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CYANOMANDELIC ACID ETHYL ESTER(847227-46-7)
• EPA Substance Registry System: 4-CYANOMANDELIC ACID ETHYL ESTER(847227-46-7)

Safety Data

• Hazardous Substances Data: 847227-46-7(Hazardous Substances Data)

Upstream product

• 302912-31-8 ethyl-4-cyanobenzoylformate 
• 924-44-7 glyoxylic acid ethyl ester 
• 126747-14-6 4-cyanophenylboronic acid 

Downstream Products

• 1221966-53-5 ethyl 2-(4-cyanophenyl)-2-(methylsulfonyloxy)acetate 
• 1344706-07-5 (R/S)-N-(cyanomethyl)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide 
• 1344706-05-3 (R/S)-2-hydroxy-N-(2-hydroxyethyl)-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide 
• 1344706-04-2 (R/S)-N-(2-amino-2-oxoethyl)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide 
• 1344706-03-1 (R/S)-2-hydroxy-N-(2-(methylamino)-2-oxoethyl)-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide 
• 1344708-47-9 (R/S)-2-hydroxy-2-(4-(5-(5-phenyl-4-(trifluoromethyl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetic acid 
• 1344708-46-8 (R/S)-ethyl 2-hydroxy-2-(4-(5-(5-phenyl-4-(trifluoromethyl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetate 
• 1344708-45-7 (R/S)-2-hydroxy-2-(4-(5-(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetic acid 
• 1344708-44-6 (R/S)-ethyl 2-hydroxy-2-(4-(5-(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetate 
• 1344708-41-3 (R/S)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetic acid 
• 1344708-40-2 (R/S)-ethyl 2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetate 
• 1344708-39-9 (R/S)-(E/Z)-ethyl 2-hydroxy-2-(4-(N'-hydroxycarbamimidoyl)phenyl)acetate 
• 1344707-97-6 (R/S)-2-hydroxy-N-(2-(1-methylpyrrolidin-2-yl)ethyl)-2-(4-(5-(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide 
• 1344707-65-8 (R/S)-2-hydroxy-N-((3-isopropylisoxazol-5-yl)methyl)-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide 

Relevant articles and documents

Biocatalysed reductions of α-ketoesters employing CyreneTM as cosolvent

The search for novel reaction media with environmental friendly properties is an area of great interest in enzyme catalysis. Water is the medium of biocatalysed processes, but due to its properties, sometimes the presence of organic (co)solvents is required. CyreneTM represents one of the newest approaches to this medium engineering. This polar solvent has been employed for the first time in biocatalysed reductions employing purified alcohol dehydrogenases. A set of α-ketoesters has been reduced to the corresponding chiral α-hydroxyesters with high conversions and optical purities, being possible to obtain good results at Cyrene contents of 30% v/v and working at substrate concentrations of 1.0 M in presence of 2.5% v/v of this solvent. At this concentration, the presence of Cyrene has a beneficial effect in the bioreduction conversion.

4 - (5 - ISOXAZOLYL OR 5 - PYRRAZOLYL -1,2,4- OXADIAZOL - 3 - YL) -MANDELIC ACID AMIDES AS SPHINGOSIN- 1 - PHOSPHATE 1 RRECEPTOR AGONISTS

Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: Q is, or R1 is phenyl substituted with zero to 3 substituents; and R1, R2, R3, R4, R5, and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Generation of iminyl copper species from α-azido carbonyl compounds and their catalytic C-C bond cleavage under an oxygen atmosphere

Figure presented A copper-catalyzed reaction of α-azidocarbonyl compounds under an oxygen atmosphere is reported where nitriles are formed via C-C bond cleavage of a transient iminyl copper intermediate. The transformation is carried out by a sequence of denitrogenative formation of iminyl copper species from α-azidocarbonyl compounds and their C-C bond cleavage, where molecular oxygen (1 atm) is a prerequisite to achieve the catalytic process and one of the oxygen atoms of O2 was found to be incorporated into the β-carbon fragment as a carboxylic acid.

Suzuki-Miyaura coupling reaction of boronic acids and ethyl glyoxylate: Synthetic access to mandelate derivatives

The palladium-catalyzed coupling reaction of arylboronic acids with ethyl glyoxylate provides a straightforward method for the synthesis of mandelic esters. Pd2(dba)3·CHCl3 in combination with 2-di-tert-butylphosphanylbiphenyl as the catalytic system and Cs 2CO3 as the base were used. The reaction tolerates a wide range of functionalized boronic acids. Mandelic esters were isolated in good-to-excellent yields with a variety of neutral, slightly electron-rich, and slightly electron-poor substituents. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.